Scott Ullem will step down as Chief Financial Officer of Edwards Lifesciences by mid‑2026 and will remain in an advisory capacity after a successor is named.
Ullem has served as CFO since 2014, overseeing the company’s financial strategy during a period of significant growth in its structural‑heart portfolio, including the acquisition of JenaValve Technology and Endotronix in 2024.
In the third quarter of 2025, Edwards Lifesciences reported sales of $1.55 billion, a 14.7% year‑over‑year increase, and an adjusted earnings per share of $0.67. Transcatheter Mitral and Tricuspid Therapies (TMTT) sales grew 53% year‑over‑year to $144 million, while Transcatheter Aortic Valve Replacement (TAVR) sales were $4.4 billion to $4.5 billion and surgical segment sales were $1.1 billion.
Management stated that the CFO transition is part of a planned succession strategy designed to maintain continuity in financial leadership and that it will not alter the company’s current financial performance. The company will continue to focus on its growth initiatives and strategic investments in structural heart innovation.
Edwards Lifesciences remains a leading global player in structural heart devices, competing with Boston Scientific, Medtronic, and Abbott. The company’s recent acquisitions and strong quarterly results underscore its commitment to expanding its minimally invasive therapy portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.